{"schema_version":"secwatch.filing_event.v1","accession":"0001736730-26-000021","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.034035+00:00","generated_at":"2026-05-15T09:13:57.558090+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"CAMP4 appoints Michael MacLean to Board, effective April 1, 2026","bullets":["Michael MacLean, former CFO of Avidity Biosciences, joins as Class III director; board expands to 9 members.","MacLean appointed to Audit and Compensation Committees; will receive standard director compensation.","Board amended non-employee director compensation policy: new directors granted options for 56,000 shares vesting over 3 years.","MacLean brings over 35 years of financial leadership in biotech, including roles at Avidity, Akcea, PureTech, and Biogen."],"urls":{"canonical":"https://secwatch.observer/filing/0001736730-26-000021","json":"https://secwatch.observer/filing/0001736730-26-000021.json","markdown":"https://secwatch.observer/filing/0001736730-26-000021.md","text":"https://secwatch.observer/filing/0001736730-26-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000173673026000021/0001736730-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000173673026000021/camp-20260318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:13:57.558090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}